Free Trial

EyePoint Pharmaceuticals (EYPT) SEC Filings & 10K Form

EyePoint Pharmaceuticals logo
$9.17 -1.32 (-12.58%)
(As of 11/15/2024 ET)

Recent EyePoint Pharmaceuticals SEC Filings

DateFilerForm TypeView
11/14/2024
2:10 PM
Cormorant Asset Management, LP (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G/A
11/12/2024
1:31 PM
EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
11/12/2024
8:33 AM
Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G/A
11/07/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2024
7:54 AM
EyePoint Pharmaceuticals (Subject)
FEDERATED HERMES, INC. (Filed by)
FEDERATED HERMES, INC. (Filed by)
Form SC 13G
11/04/2024
10:57 AM
EyePoint Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
Form SC 13G/A
10/31/2024
3:16 PM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2024
11:51 AM
EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
Form SCHEDULE 13G/A
10/30/2024
3:20 PM
EyePoint Pharmaceuticals (Filer)
Form 424B5
10/28/2024
4:17 PM
EyePoint Pharmaceuticals (Filer)
Form 424B5
10/28/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/23/2024
3:34 PM
ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2024
2:24 PM
BlackRock, Inc. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G
10/15/2024
10:58 AM
EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/05/2024
3:02 PM
EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
3:02 PM
EyePoint Pharmaceuticals (Issuer)
Hassan Fred (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/04/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2024
3:32 PM
DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/18/2024
11:15 PM
EyePoint Pharmaceuticals (Filer)
Form EFFECT
08/08/2024
3:42 PM
EyePoint Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
08/08/2024
3:46 PM
EyePoint Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
08/07/2024
6:00 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/26/2024
3:47 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2024
3:24 PM
EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/12/2024
4:00 PM
EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/12/2024
4:03 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/12/2024
4:04 PM
Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2024
8:25 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2024
3:16 PM
ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2024
3:28 PM
EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2024
3:22 PM
Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/16/2024
4:19 PM
EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/14/2024
3:39 PM
EyePoint Pharmaceuticals (Subject)
GUYER DAVID R (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2024
9:12 AM
EyePoint Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/08/2024
3:23 PM
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/08/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2024
8:25 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/01/2024
4:08 PM
Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G/A
Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

04/30/2024
7:53 PM
Adage Capital Management, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G
04/22/2024
3:15 PM
Adage Capital Management, L.P. (Reporting)
Atchinson Robert (Reporting)
EyePoint Pharmaceuticals (Issuer)
Gross Phillip (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/02/2024
4:27 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/08/2024
12:53 PM
EyePoint Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/07/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/04/2024
4:37 PM
EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/04/2024
4:40 PM
EyePoint Pharmaceuticals (Issuer)
Ribeiro Ramiro (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
6:01 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
8:08 PM
EyePoint Pharmaceuticals (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13G/A
02/13/2024
4:37 PM
Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
4:38 PM
Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
4:38 PM
EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
4:39 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
4:40 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
11:00 AM
EyePoint Pharmaceuticals (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
Form SC 13G/A
02/07/2024
6:54 AM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13G/A
02/06/2024
9:55 AM
EyePoint Pharmaceuticals (Subject)
FRANKLIN RESOURCES INC (Filed by)
Form SC 13G/A
02/05/2024
4:15 PM
EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2024
3:22 PM
EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/30/2024
3:53 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/29/2024
4:51 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/29/2024
4:54 PM
EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
5:24 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
5:26 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2024
3:50 PM
EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2024
3:25 PM
EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2024
3:42 PM
EyePoint Pharmaceuticals (Subject)
Lurker Nancy (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2024
3:19 PM
EyePoint Pharmaceuticals (Subject)
Paggiarino Dario A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/22/2024
3:19 PM
EyePoint Pharmaceuticals (Subject)
Jones David Scott (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2024
5:55 PM
EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2024
5:01 PM
EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/11/2024
4:33 PM
EyePoint Pharmaceuticals (Subject)
Ocumension Therapeutics (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/10/2024
3:53 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/10/2024
6:05 AM
EyePoint Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/09/2024
8:28 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:17 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:53 PM
ADAMIS ANTHONY P (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:53 PM
ANDO GORAN (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:54 PM
DICICCO WENDY F (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:54 PM
Duty Stuart (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:55 PM
EyePoint Pharmaceuticals (Issuer)
Landis John B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
7:56 PM
EyePoint Pharmaceuticals (Issuer)
GUYER DAVID R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:04 PM
Elston George (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:07 PM
Duker Jay S. (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:09 PM
EyePoint Pharmaceuticals (Issuer)
Jones David Scott (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:11 PM
EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2024
8:12 PM
EyePoint Pharmaceuticals (Issuer)
Zaderej Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024
5:37 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4/A
01/02/2024
4:41 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2023
4:14 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Strange: Why is Amazon suddenly yielding 39.70%? (Ad)

Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!

Click here to see this breakthrough before everyone else →
12/12/2023
3:52 PM
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2023
4:28 PM
EW Healthcare Partners, L.P. (Filed by)
EyePoint Pharmaceuticals (Subject)
Form SC 13D/A
12/07/2023
8:21 PM
EyePoint Pharmaceuticals (Issuer)
Ocumension Therapeutics (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/07/2023
8:03 PM
EyePoint Pharmaceuticals (Issuer)
Liu Ye (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/07/2023
5:11 AM
EyePoint Pharmaceuticals (Filer)
Form 424B5
12/06/2023
4:18 PM
EyePoint Pharmaceuticals (Issuer)
Lurker Nancy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
4:19 PM
EyePoint Pharmaceuticals (Issuer)
Paggiarino Dario A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
4:20 PM
EyePoint Pharmaceuticals (Issuer)
Pine Michael Craig (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
3:39 PM
Chen Bihua (Reporting)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
EyePoint Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:EYPT) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners